Mega Genomics Limited

HKSE 6667.HK

Mega Genomics Limited Total Non-Current Liabilities for the year ending December 31, 2023: USD 5.27 M

Mega Genomics Limited Total Non-Current Liabilities is USD 5.27 M for the year ending December 31, 2023, a 462.83% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Mega Genomics Limited Total Non-Current Liabilities for the year ending December 31, 2022 was USD 935.54 K, a -24.72% change year over year.
  • Mega Genomics Limited Total Non-Current Liabilities for the year ending December 31, 2021 was USD 1.24 M, a -45.24% change year over year.
  • Mega Genomics Limited Total Non-Current Liabilities for the year ending December 31, 2020 was USD 2.27 M, a -92.59% change year over year.
  • Mega Genomics Limited Total Non-Current Liabilities for the year ending December 31, 2019 was USD 30.64 M.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
Loading...
SV Wall Street
HKSE: 6667.HK

Mega Genomics Limited

CEO Ms. Lin Lin
IPO Date June 22, 2022
Location China
Headquarters 401 Health Work
Employees 214
Sector Health Care
Industries
Description

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services comprising ApoE gene testing package that assesses the lipid metabolism capacity and the risk for various related diseases, including Alzheimer's disease; folate metabolic capacity assessment, which analyzes genes related to folate metabolism capacity to determine the risk of developing hyperhomocysteinemia, cardiovascular, and cerebrovascular diseases; Parkinson's disease risk assessment; full-scale cancer risk assessment package; and cardiovascular and cerebrovascular disease risk assessment package. The company also provides advanced testing services, which include Hereditary breast cancer/ovarian cancer genetic testing, Septin9 colorectal cancer screening test, and RNF180/Septin9 gastric cancer screening test; and executive testing services, such as personal whole genome test and whole-exome sequencing package for adults. It offers testing services through self-developed laboratory-developed tests and In-vitro diagnostics testing kits. The company serves health checkup centers, hospitals, and various other customers. Mega Genomics Limited was founded in 2016 and is based in Beijing, China.

Similar companies

6639.HK

Arrail Group Limited

USD 0.34

17.24%

6680.HK

JL Mag Rare-Earth Co., Ltd.

USD 1.17

-3.31%

6669.HK

Acotec Scientific Holdings Limited

USD 0.79

7.30%

StockViz Staff

January 31, 2025

Any question? Send us an email